Boers M - Search Results

1

The OMERACT filter for Outcome Measures in Rheumatology.

Boers M, Brooks P, Strand CV, Tugwell P. Boers M, et al. J Rheumatol. 1998 Feb;25(2):198-9. J Rheumatol. 1998. PMID: 9489805 No abstract available.

2

Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III.

Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M. Bellamy N, et al. Among authors: boers m. J Rheumatol. 1997 Apr;24(4):799-802. J Rheumatol. 1997. PMID: 9101522 Review.

3

OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction.

Tugwell P, Boers M. Tugwell P, et al. Among authors: boers m. J Rheumatol. 1993 Mar;20(3):528-30. J Rheumatol. 1993. PMID: 8478864 Review. No abstract available.

4

Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials.

Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Lassere MN, et al. Among authors: boers m. J Rheumatol. 2001 Apr;28(4):892-903. J Rheumatol. 2001. PMID: 11327273

5

Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference.

Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M, Strand V, Shea B. Beaton DE, et al. Among authors: boers m. J Rheumatol. 2001 Feb;28(2):400-5. J Rheumatol. 2001. PMID: 11246687 Review.

6

Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology.

Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M. Wolfe F, et al. Among authors: boers m. J Rheumatol. 1999 Feb;26(2):484-9. J Rheumatol. 1999. PMID: 9972992

7

Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology.

Gazarian M, Tugwell P, Boers M, Bombardier C, Brooks P, Day R, Strand V, Wells G. Gazarian M, et al. Among authors: boers m. J Rheumatol. 1999 Jan;26(1):207-9. J Rheumatol. 1999. PMID: 9918265

8

Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee.

Goldsmith CH, Boers M, Bombardier C, Tugwell P. Goldsmith CH, et al. Among authors: boers m. J Rheumatol. 1993 Mar;20(3):561-5. J Rheumatol. 1993. PMID: 8478874

9

Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee.

Tugwell P, Boers M. Tugwell P, et al. Among authors: boers m. J Rheumatol. 1993 Mar;20(3):555-6. J Rheumatol. 1993. PMID: 8478872 Review. No abstract available.

10

A method for achieving consensus on rheumatoid arthritis outcome measures: the OMERACT conference process.

Fried BJ, Boers M, Baker PR. Fried BJ, et al. Among authors: boers m. J Rheumatol. 1993 Mar;20(3):548-51. J Rheumatol. 1993. PMID: 8478870 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results